Frequency of anti-heparin-PF4 complex antibodies (HIT Antibodies) in uremic patients on chronic intermittent hemodialysis

Pathophysiology of Haemostasis and Thrombosis

Volumn 35, Issue 6, 2006, Pages 445-450

  Matsuo, Takefumi ^a   Kobayashi, Hiroko ^b   Matsuo, Miyako ^a   Wanaka, Keiko ^b   Nakamoto, Hidetomo ^c   Matsushima, Hiroyuki ^d   Sakai, Rumi ^e  

^a HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^b Kobe Research Projects on Thrombosis and Haemostasis   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^e Sakai Rumi Clinic   (Japan)

Author keywords

Hemodialysis; Heparin platelet factor 4 complex antibodies; Thrombocytopenia; Uremia

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; UREMIA;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RENAL DIALYSIS; THROMBOSIS; UREMIA;

EID: 34250196449     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102052     Document Type: Article

References (18)

1. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T: Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996;28:82-85.
2. Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A: Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998;89:115-122.
3. O'Shea SI, Sands JJ, Nudo SA, Ortel TL: Frequency of anti-heparin- platelet 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 2002;69:72-73.
4. Boon DMS, van Vliet HHDM, Zietse R, Kappers-Klunne MC: The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 1996;76:480.
5. de Sancho M, Lema MG, Amiral J, Rand J: Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. Thromb Haemost 1996;75:695-696.
6. Finazzi G, Remuzzi G: Heparin-induced thrombocytopenia - background and implications for haemodialysis. Nephrol Dial Transplant 1996;11:2120-2122.
7. Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D: Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 2004;136:848-853.
8. Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-157.
9. Sitter T, Spannagl M, Banas B, Schiffl H: Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998;79:245-246.
10. Palomo I, Pereira J, Alarcon M, Diaz G, Hidalgo P, Pizarro I, Jara E, Rojas P, Quiroga G, Moore-Carrasco R: Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 2005;19:189-195.
11. Yu A, Jacobson SH, Bygden A, Egberg N: The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 2002;40:21-26.
12. Pena VL, Miller RS, Benda MM, Grill DE, Johnson MG, McCarthy JT, McBane RD: Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc 2005;80:988-990.
13. Greinacher A, Zinn S, Wizemann U, Birk W: Heparin-induced antibodies as a risk factor for thromboembolism undergoing chronic haemodialysis. Lancet 1996;348:764.
14. Matsuo T, Yamada T, Chikahira Y, Kadowaki S: Effect of aspirin on heparin-induced thrombocytopenia in a patient requiring hemodialysis. Blut 1989;59:393-395.
15. Sayinalp N, Erdem Y, Ilhami Ozcebe O, Buyukasik Y, Caglar S, Dundar SV: Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients. Thromb Res 1998;90:195-198.
16. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H: Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002;62:1757-1763.
17. Stasko J, Funiak S, Funakova S, Peterkova M, Ivankova J, Makovicky P, Kubisz P: Some hemostatic changes during the course of hemodialysis in patients with erythropoietin treatment. Clin Appl Thromb Hemost 1997;3:141-143.
18. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.